Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
5.96M
-
Shares change
-
+2.17M
-
Total reported value, excl. options
-
$37M
-
Value change
-
+$14M
-
Put/Call ratio
-
0.68
-
Number of buys
-
39
-
Number of sells
-
-9
-
Price
-
$6.20
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q2 2024
54 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2024.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.96M shares
of 49.6M outstanding shares and own 12.01% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1.94M shares), BlackRock Inc. (823K shares), VANGUARD GROUP INC (819K shares), STATE STREET CORP (473K shares), Sands Capital Ventures, LLC (406K shares), GEODE CAPITAL MANAGEMENT, LLC (398K shares), Nuveen Asset Management, LLC (382K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (80.6K shares), MML INVESTORS SERVICES, LLC (73.4K shares), and Bank of New York Mellon Corp (54.4K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.